名臣健康(002919) - 2025 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2025 reached ¥367,205,252.81, an increase of 14.73% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 95.92% to ¥1,487,200.83, while the net profit after deducting non-recurring gains and losses fell by 98.79% to ¥453,149.64[5] - Total operating revenue for the current period reached ¥1,078,874,052.86, an increase of 9.57% compared to ¥984,704,973.19 in the previous period[26] - Net profit for the current period was ¥42,403,252.01, a decrease of 56.14% from ¥96,790,316.11 in the previous period[27] - Basic earnings per share for the current period were ¥0.1596, down from ¥0.3631 in the previous period[28] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥1,172,132,210.48, reflecting a growth of 6.23% from the end of the previous year[5] - Total assets increased to ¥1,172,132,210.48, compared to ¥1,103,346,118.01 in the previous period, reflecting a growth of 6.26%[24] - Total liabilities rose to ¥350,698,567.24, an increase of 25.14% from ¥280,009,676.12 in the previous period[24] - The company’s intangible assets increased by 92.14% to ¥291,065,108.53, reflecting ongoing development projects[9] - Deferred income tax assets increased to ¥91,267,889.99 from ¥76,855,644.74, marking a rise of 18.67%[24] Cash Flow - The company reported a 29.60% decline in net cash flow from operating activities, totaling ¥39,902,804.53 for the year-to-date[13] - Operating cash inflow for the current period was CNY 928,187,653.55, a slight increase from CNY 922,951,805.76 in the previous period[29] - Net cash outflow from operating activities was CNY 39,902,804.53, down from CNY 56,678,574.83 in the previous period[30] - Cash inflow from investment activities totaled CNY 238,666,204.95, compared to CNY 149,815,082.81 in the previous period[30] - Cash inflow from financing activities was CNY 30,014,544.16, with a net cash outflow of CNY 26,491,701.20, compared to a net outflow of CNY 49,781,796.36 in the previous period[30] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,452[15] - The largest shareholder, Chen Qinfang, holds 35.02% of shares, totaling 93,338,604 shares, with 14,644,000 shares pledged[15] - The company plans to repurchase shares using its own funds, with a total repurchase amount between RMB 30 million and RMB 50 million, at a price not exceeding RMB 23 per share[18] - As of September 30, 2025, the company has repurchased a total of 2,249,700 shares, representing 0.84% of the total share capital[20] Operating Costs and Expenses - Total operating costs amounted to ¥1,031,137,681.82, up 21.06% from ¥852,236,672.12 in the prior period[26] - The company’s financial expenses surged by 205.99% to ¥398,255.73, primarily due to reduced foreign exchange gains[12] - Research and development expenses for the current period were ¥40,483,039.47, down 17.16% from ¥48,895,920.66 in the previous period[27] - Cash paid for purchasing goods and services was CNY 622,079,280.28, an increase from CNY 583,529,139.50 in the previous period[30] - Cash paid to employees decreased to CNY 144,728,270.05 from CNY 171,317,281.65 in the previous period[30] Accounts Receivable and Payable - The company’s accounts payable rose by 57.66% to ¥200,334,768.73, driven by increased game distribution and publishing costs[9] - The company reported a significant increase in accounts payable, which rose to ¥200,334,768.73 from ¥127,066,568.53, representing a growth of 57.59%[24] - Accounts receivable decreased from RMB 241,718,639.65 to RMB 236,124,451.25 during the reporting period[21] - Prepayments decreased from RMB 124,671,876.03 to RMB 80,890,476.44[21] Other Information - The company has not disclosed any significant new product developments or market expansions in the current reporting period[18] - There are no reported changes in the top 10 shareholders due to share lending or borrowing activities[16]